While chemotherapy remains a foundational option in the first-line setting—especially in advanced stages—the use of maintenance hormonal therapy is increasingly supported across guidelines, mirroring treatment strategies seen in hormone receptor–positive breast cancer. The gene discussed is NR4A1; the disease is breast cancer.